Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B cell-tailored versus standard ocrelizumab in relapsing-remitting multiple sclerosis
NL-OMON52141Phase 4Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Vrije University Medical Center. Primary endpoint: Relapses and new/enlarging T2 lesions on MRI. Started Apr 2022; status: recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON52141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52141.